Assessment of Stent Strut Coverage and Endothelial Function After Drug-Eluting Stents (ASSESS)

Hyogo Medical University

Status

Withdrawn

Conditions

Coronary Artery Disease

Atherosclerosis

Treatments

Device: sirolimus-eluting stents (CYPHER SELECT® PLUS)

Device: everolimus-eluting stents (PROMUS®)

Device: zotarolimus-eluting stent (ENDEAVOR®)

Study type

Interventional

Funder types

Other

Identifiers

NCT01073111

ASSESS

Details and patient eligibility

About

The purpose of this study is to compare coronary endothelium function in patients with a zotarolimus-eluting versus a sirolimus-eluting or a everolimus-eluting stents with optical coherence tomography, vasoconstriction in response to acetylcholine, and coronary biomarker level.

Sex

All

Ages

25 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Significant coronary de novo lesion (> 70% by quantitative angiographic analysis)
Patients with stable or acute coronary syndrome considered for coronary revascularization
Reference vessel diameter of 2.5 to 3.5 mm by operator assessment

Exclusion criteria

Contraindication to anti-platelet agents
Ostial lesion within 5 mm from ostium
Different DES in other vessel simultaneously
Creatinine level 2.5 mg/dL
Left main stenosis more than 50%.
vein graft lesion
Triple vessel disease with stenosis more than 50% in 3 epicardial coronary arteries
Life expectancy 1 year
Reference vessel < 2.5 mm or > 4.0 mm diameter by visual
Long lesion that require more than three stents